Rationale for LDH-targeted cancer immunotherapy

Miholjcic, T. B. S., Halse, H., Bonvalet, M., Bigorgne, A., Rouanne, M., Dercle, L., Shankar, V., & Marabelle, A. (2023). Rationale for LDH-targeted cancer immunotherapy. European Journal of Cancer, 181, 166–178. https://doi.org/10.1016/j.ejca.2022.11.032
Authors:
Tina B S Miholjcic
Heloise Halse
Mélodie Bonvalet
Amélie Bigorgne
Mathieu Rouanne
Laurent Dercle
Vishnu Shankar
Aurélien Marabelle
Affiliated Authors:
Mathieu Rouanne
Laurent Dercle
Columbia Affiliation:
Subjects:
Immunotherapy (MeSH)
L-Lactate Dehydrogenase (MeSH)
Neoplasms (MeSH)
Author Keywords:
cancer
immunosuppression
immunotherapy
lactate dehydrogenase (ldh)
elink
Publication Type:
Article
Unique ID:
10.1016/j.ejca.2022.11.032
PMID:
36657325
DOI:
10.1016/j.ejca.2022.11.032
Journal:
European Journal of Cancer
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record

Record Created: